Literature DB >> 28277060

Thrombelastographic hypercoagulability and antiplatelet therapy after coronary artery bypass surgery (TEG-CABG trial): a randomized controlled trial.

Sulman Rafiq1, Pär I Johansson2, Klaus F Kofoed3, Jens T Lund1, Peter S Olsen1, Simon Bentsen1, Daniel A Steinbrüchel1.   

Abstract

A hypercoagulable state has, in observational studies, been associated with increased risk of thromboembolic events. The aim of this trial was to study whether dual antiplatelet therapy (DAPT) with clopidogrel in addition to aspirin could reduce the rate of graft occlusions, thromboembolic events, and death compared to aspirin monotherapy in hypercoagulable patients undergoing coronary artery bypass surgery. A total of 1683 patients were screened for eligibility, among which 165 patients were randomized and 133 patients underwent multislice computed tomography scan to evaluate their grafts. Thrombelastography (TEG) and multiplate aggregometry were performed before and after surgery, and again at three months follow up. TEG hypercoagulability was defined as the maximum amplitude above 69 mm. At three months follow up, 17 out of 66 (25.7%) DAPT patients and 15 of 67 (22.4%) aspirin patients had significant graft stenosis or occlusions (p = 0.839). Saphenous vein grafts (SVGs) were stenosed or occluded in 15 (22.7%) patients in the DAPT group and 7 (10.4%) in the aspirin group (p = 0.167). Thromboembolic events and death after the second postoperative day (when clopidogrel was started) were numerically, but not statistically, lower in the DAPT group, 3 (3.8%) vs. 8 (9.9%), p = 0.211. In univariate logistic regression analysis, only postoperative day 4 platelet response to aspirin measured with multiplate was correlated with graft occlusion, OR 1.020 [1.002-1.039], p = 0.033. This is the first trial to test the hypothesis of intensified antiplatelet therapy in hypercoagulable patients. Due to the low enrollment and high loss to follow up, our results can only be viewed as hypothesis generating. We found a high rate of graft occlusions in this patient population. Our results were not suggestive of that DAPT improved saphenous vein graft patency. A trend was observed in patients on DAPT toward fewer MI and deaths. Postoperative response to aspirin therapy was found to be associated with early SVG occlusion.

Entities:  

Keywords:  CABG; TEG; coronary artery bypass surgery; dual antiplatelet therapy; hypercoagulable; multiplate aggregometry

Mesh:

Substances:

Year:  2017        PMID: 28277060     DOI: 10.1080/09537104.2017.1280147

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  5 in total

1.  Using Thromboelastography to Predict Blood Loss After Off-Pump Coronary Artery Bypass Grafting.

Authors:  Yu Liu; Wen-Li Zhang; Ji-Qiang Bu; Jian-Jun Gu; Yong-Quan Sun; Hong-Zhan Cui; Da-Wei Wang; Zi-Ying Chen
Journal:  Int J Gen Med       Date:  2021-03-19

Review 2.  Management and Prevention of Saphenous Vein Graft Failure: A Review.

Authors:  Peter McKavanagh; Bobby Yanagawa; George Zawadowski; Asim Cheema
Journal:  Cardiol Ther       Date:  2017-07-26

3.  Hypercoagulability as Measured by Thrombelastography May Be Associated with the Size of Acute Ischemic Infarct-A Pilot Study.

Authors:  Adam Wiśniewski; Aleksandra Karczmarska-Wódzka; Joanna Sikora; Przemysław Sobczak; Adam Lemanowicz; Karolina Filipska; Robert Ślusarz
Journal:  Diagnostics (Basel)       Date:  2021-04-15

4.  Development and Validation of a Novel Tool for the Prediction of Clopidogrel Response in Chinese Acute Coronary Syndrome Patients: The GeneFA Score.

Authors:  Hongyi Wu; Xiaoye Li; Juying Qian; Xin Zhao; Yao Yao; Qianzhou Lv; Junbo Ge
Journal:  Front Pharmacol       Date:  2022-03-21       Impact factor: 5.810

5.  Network meta-analysis of antiplatelet therapy following coronary artery bypass grafting (CABG): none versus one versus two antiplatelet agents.

Authors:  Adam Chakos; Dean Jbara; Kamal Singh; Tristan D Yan; David H Tian
Journal:  Ann Cardiothorac Surg       Date:  2018-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.